Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 124 Cr.
- Current Price ₹ 232
- High / Low ₹ 316 / 175
- Stock P/E 15.5
- Book Value ₹ 66.2
- Dividend Yield 0.00 %
- ROCE 35.2 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 136 days to 85.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 17.80 | 61.73 | 83.19 | |
| 15.54 | 52.85 | 71.70 | |
| Operating Profit | 2.26 | 8.88 | 11.49 |
| OPM % | 12.70% | 14.39% | 13.81% |
| 0.03 | 0.08 | 0.08 | |
| Interest | 0.09 | 0.21 | 0.55 |
| Depreciation | 0.01 | 0.02 | 0.03 |
| Profit before tax | 2.19 | 8.73 | 10.99 |
| Tax % | 27.85% | 27.49% | |
| 1.59 | 6.33 | 8.02 | |
| EPS in Rs | 3.24 | 12.74 | 15.56 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 152% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 4.90 | 4.97 | 5.35 |
| Reserves | 13.32 | 22.77 | 30.04 |
| 1.60 | 3.26 | 6.87 | |
| 0.96 | 4.57 | 9.25 | |
| Total Liabilities | 20.78 | 35.57 | 51.51 |
| 0.05 | 1.65 | 1.73 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.42 | 0.43 | 0.43 |
| 20.31 | 33.49 | 49.35 | |
| Total Assets | 20.78 | 35.57 | 51.51 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -3.87 | 1.21 | |
| -0.52 | -1.56 | |
| 13.13 | 2.86 | |
| Net Cash Flow | 8.74 | 2.50 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 66.03 | 86.09 |
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | 66.03 | 86.09 |
| Working Capital Days | 186.81 | 85.56 |
| ROCE % | 35.18% |
Documents
Announcements
-
Submission Of Unaudited Standalone And Consolidated Financial
Results For The Half-Year Ended 30Th September, 2025 Pursuant To Regulation 33 Of
SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015.
13 Nov - Approved unaudited H1 results (ended 30 Sep 2025); limited review and preferential issue utilization certificate attached.
-
Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015.
13 Nov - Board approved unaudited H1 results; standalone PAT ₹195.31L, consolidated PAT ₹405.60L; utilization certificate enclosed.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29(1)(A) Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015
7 Nov - Board meeting on 13 Nov 2025 to approve unaudited results for half-year ended 30 Sep 2025; trading window closed.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 16 Oct
-
Disclosure Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 - Alteration In Memorandum Of Association ("MOA") Of Royal Sense Limited.
30 Sep - Special resolution at AGM (30 Sep 2025) approved alteration to Memorandum of Association; revised MOA attached.
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.